Back to top
more

ADMA Biologics (ADMA)

(Real Time Quote from BATS)

$19.81 USD

19.81
724,065

+0.14 (0.71%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

by Zacks Equity Research

Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.

Kanishka Das headshot

Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up

by Kanishka Das

Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

by Zacks Equity Research

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 33.56%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.

Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use

by Zacks Equity Research

J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.

Adma Biologics (ADMA) Stock Moves -0.5%: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed at $5.99 in the latest trading session, marking a -0.5% move from the prior day.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

by Zacks Equity Research

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use

by Zacks Equity Research

Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

by Zacks Equity Research

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

by Zacks Equity Research

AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.

Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab

by Zacks Equity Research

Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

by Zacks Equity Research

Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.

NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up

by Zacks Equity Research

NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

by Zacks Equity Research

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

by Zacks Equity Research

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study

by Zacks Equity Research

Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why

by Zacks Equity Research

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

by Zacks Equity Research

Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

by Zacks Equity Research

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.